|
NEW YORK (AP) - Shares of Nabi Biopharmaceuticals climbed Wednesday, after the company said it will continue developing two drugs targeting gram-positive bacterial infections, such as staph infections, after an outside advisery panel assessed the prospects for the products.
Stock of the Boca Raton, Fla.-based company rose 72 cents, or 15 percent, to $5.52 in early afternoon trading on the Nasdaq Stock Market.
Wednesday's strongest level, on heavy volume, was $5.67. On a 52-week basis, there was a high of $16 on July 6 and a low of $3.06 on Nov. 29.
|
|